The New Molecules Committee (CMN) of the Federal Commission for the Protection against Sanitary Risks (Cofepris) of Mexico issued a favorable opinion on the recombinant protein vaccine of the receptor binding domain of the SARS-CoV-2 virus, known as Abdala.
The vaccine, developed by the Center for Genetic Engineering and Biotechnology (CIGB) of the Republic of Cuba, is indicated for specific active immunization against SARS-CoV-2 infection, in children from 5 years of age, with efficacy to mild, moderate and severe clinical forms of COVID-19 of 92.13 percent, 88.99 percent and 92.33 percent, respectively.
It should be noted that the opinion issued by the CMN is part of the process to obtain emergency use authorization issued by the Cofepris Health Authorization Commission, once the information presented has been evaluated.
Likewise, it is reported that on April 3, the Abdala vaccine obtained from the National Committee of Science, Technology and Innovation in Public Health (CNCTI-SP), of the now National Council of Humanities, Sciences and Technologies (Conahcyt) a favorable recommendation for the extension of the indication of emergency use of the Abdala vaccine against COVID-19 for primary vaccination in pediatric population from 5 to 17 years old.
Since 2021, the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed) of Cuba authorized the emergency use of this vaccine in that country, confirming that it met the requirements and parameters demanded in terms of quality, safety and efficacy.
(With information from Cofepris)